Dishman Carbogen Amcis Ltd

- There is no explicit mention of any new fundraising through debt or equity in the provided transcript. - The company is focused on reducing net debt by INR 100 to 200 crores annually through free cash flow generation. - Most large CAPEX (e.g., French facility, digital transformation) is behind them, and future CAPEX will be based on proper business cases with customer commitments. - The management emphasizes generating free cash flow and avoiding sales that reduce profitability just to increase revenues. - Co-investment agreements with customers, such as the Japanese innovator investing EUR 25 million, are structured with customer payments funding infrastructure rather than the company raising external funds. - Debt costs are expected to decrease due to lower interest rates and goodwill amortization reduction.

- FY ‘26 CAPEX guidance is approximately INR 250 crores to INR 300 crores (EUR 25-30 million). - Maintenance CAPEX is around INR 170-180 crores; the remainder is growth CAPEX including digital transformation initiatives. - Large CAPEX for the French entity is mostly behind; future CAPEX will focus on expansion based on confirmed business cases. - Co-investment of EUR 25 million by a Japanese customer for a specific project; infrastructure investment is a core investment paid by the client. - Additional investments are planned in product expansion projects in Europe and India. - Focus on CAPEX only when there is committed revenue from customers to ensure returns. - Capital expenditure includes upgrades at Bavla and Naroda sites to support a peak revenue potential of INR 800 crores for India assets. - Discussions continue on alliances and strategic investments to support growth and business expansion.

- The company targets a low double-digit revenue growth, aiming for a CAGR of 12% to 15% over the next 3 to 5 years. (Page 10) - India CRAMS business is expected to grow by 15% to 20% in FY ‘26. (Page 9) - The Quats and Generics business is expected to grow between 5% to 10%. (Page 9) - Peak revenue from India assets could reach around INR 800 crores within 2 to 3 years. (Pages 13-14) - Bavla site's quarterly revenue is anticipated to reach around INR 100 crores in the later part of FY ‘26. (Page 15) - EBITDA targeted at INR 550 crores to INR 570 crores in FY ‘26, with potential for higher margins than 20%. (Page 22) - The company is focusing on collaboration and transferring production of molecules to India for improved utilization and margin. (Pages 13-14) - Expansion efforts include exploring new markets outside the U.S. and investing in value-added products like ADCs and conjugates. (Pages 11, 21)

- EBITDA for FY '26 is expected between INR 550 crores to INR 570 crores, targeting a 20% margin. - Revenue growth target is low double digits annually, aiming for sustained profitability alongside revenue increase. - Operating profit (EBITDA) is projected to reach around INR 750 crores within the next 2 to 3 years. - ROCE is currently low (~2%) but expected to improve to double digits (13%-15%) within 3 years due to ramp-up of various business entities. - Free cash flow generation is prioritized with a plan to reduce net debt by INR 100-200 crores annually. - Profit after tax (PAT) should improve with decreasing interest costs and amortization, though tax rate is likely to stay around 25%-30% effective. - Margins in Indian CRAMS business targeted at 20-25%, with overall company EBITDA margin aiming at 20% in FY '26. - EPS growth expected in line with EBITDA and revenue growth as profitability and efficiencies improve.

- The transcript does not explicitly mention the current or expected order book or pending orders by a specific value. - However, the discussion indicates a positive outlook on upcoming projects, with a focus on early-phase and late-phase (Phase IIb and Phase III) projects. - The company is investing in market intelligence to identify new opportunities and potentially become a secondary supplier for risk mitigation. - There is a mention of strong interest and investment in the CRAMS business and API development with expected growth. - A co-investment of EUR 25 million with a Japanese innovator was noted, reflecting confidence from clients and a strong project pipeline. - Revenue targets imply growing order inflows to meet EBITDA of INR 550-570 crores expected for FY ‘26, and longer-term EBITDA target of INR 750 crores in 2-3 years.